Skip to main content

Clinical Trial Search Results

A scientist pointing to an image of a DNA chain.

Clinical Trial Search Results

Showing 136-144 out of 318 results.
NCT05165433

NG-350A-02: A multicentre, open-label, non-randomized, phase 1a/1b study of NG-350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours (FORTIFY)

Icon for trial | NG-350A-02 NG-350A-02: A multicentre, open-label, non-randomized, phase 1a/1b study of NG-350A, a tumour-selective anti-CD40-expressing adenoviral vector, in combination with pembrolizumab in patients with metastatic or advanced epithelial tumours (FORTIF

This study is currently enrolling.

The purpose of this research study is to test how safe and well-tolerated treatment with the study drug is in combination with pembrolizumab and to find out more about the side-effects. The study aims to determine the following ...

NCT06131372

NN9388-7700: Efficacy and safety of co-administered cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (cagrisema s.c. 2.4 mg/2.4 mg) once-weekly compared to semaglutide, cagrilinitide and placebo in people with chronic kidney disease and type 2 diabetes.

Icon for trial | NN9388-7700: Efficacy and safety of co-administered cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (cagrisema s.c. 2.4 mg/2.4 mg) once-weekly compared to semaglutide, cagrilinitide and placebo in people with chronic kidney disease an

This study is currently enrolling.

Study Purpose: The purpose of this study is to see whether CagriSema can lower kidney damage. This will be compared to the effects of semaglutide, cagrilintide and placebo. Study Duration: Approximately 35 weeks Study Commitmen ...

NCT05256225

NRG-GY026: A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL SEROUS CARCINOMA OR CARCINOSARCOMA

Icon for trial | NRG GY026 NRG-GY026: A PHASE II/III STUDY OF PACLITAXEL/CARBOPLATIN ALONE OR COMBINED WITH EITHER TRASTUZUMAB AND HYALURONIDASE-OYSK (HERCEPTIN HYLECTA) OR PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF (PHESGO) IN HER2 POSITIVE, STAGE I-IV ENDOMETRIAL S

This study is currently enrolling.

This study has public funding from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH) in the United States Department of Health and Human Services. We do research studies to try to answer quest ...